Menu
Not yet recruiting NCT07270809

To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.

Observational Chronic Liver Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No Intervention.
Who it may be relevant to
Registry conditions: Chronic Liver Disease. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
India
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Title - To study the clinical course and outcomes of non-electively hospitalised patients of chronic liver disease (CLD) with Hepatic or Extra-hepatic predominant organ failure(s) at 6 months. Summary - ACLF is a condition where acute insult leading to worsening liver failure with or without extra-hepatic failure leads to a high short-term mortality. However, the presence of cirrhosis, prior decompensation, non-hepatic/systemic acute insult, organ failure and treatment are different in different part of the world. This is due to in-homogenous patient cohort. The current study was planned for all patients of CLD, who were non-electively hospitalized and were followed up for long-term to identify the differences in clinical course, acute insult, organ failure, therapy and outcome in relation to liver failure with or without extra-hepatic organic failure. In the study the laboratory, clinical parameters, inflammatory and regenerative markers will be evaluated as a marker of disease progression, reversal, recompensation or regression. This will enable us to differentiate the ACLF between east and west, guide us for defining the natural course of CLD with failure.

Interventions

  • Other No Intervention
    No Intervention

Primary outcome measures

  • Death or liver transplant at 6 months follow up. [Time frame: 6 months]
Secondary outcome measures (2)
  • Recovery as per disease severity scores, i.e- decrease in MELD ≥5 and CTP ≥3 [Time frame: 6 months]
  • Organ dysfunction and organ failures [Time frame: day 28, day 90, day 180]

Eligibility criteria

Inclusion criteria

  • Age 18-70 years
  • CLD with or without cirrhosis with 1st or subsequent admissions for decompenasation and irrespective of any prior decompensation
  • Non-electively hospitalized

Exclusion criteria

  • HCC
  • NCPF/EHPVO
  • Pregnancy
  • Post-Liver transplant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

India · 1 center
  • Institute of Liver & Biliary Sciences (ILBS) — New Delhi

Identifiers

NCT: NCT07270809 · ILBS-CLD-66

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗